Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 2,250,000 shares, an increase of 10.3% from the May 31st total of 2,040,000 shares. Approximately 10.3% of the company’s shares are short sold. Based on an average daily trading volume, of 327,800 shares, the short-interest ratio is currently 6.9 days.
Akoya Biosciences Stock Performance
Shares of NASDAQ:AKYA opened at $2.21 on Tuesday. The business has a 50-day moving average of $2.81 and a two-hundred day moving average of $4.21. The firm has a market capitalization of $109.15 million, a PE ratio of -1.50 and a beta of 1.34. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.07 and a quick ratio of 2.38. Akoya Biosciences has a 12 month low of $1.88 and a 12 month high of $7.68.
Akoya Biosciences (NASDAQ:AKYA – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). Akoya Biosciences had a negative return on equity of 111.80% and a negative net margin of 72.68%. The firm had revenue of $18.35 million for the quarter, compared to analysts’ expectations of $24.13 million. As a group, research analysts forecast that Akoya Biosciences will post -0.99 earnings per share for the current year.
Institutional Trading of Akoya Biosciences
Analysts Set New Price Targets
A number of brokerages recently issued reports on AKYA. Canaccord Genuity Group decreased their target price on shares of Akoya Biosciences from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, May 14th. BTIG Research decreased their price objective on Akoya Biosciences from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, May 14th. UBS Group upped their target price on Akoya Biosciences from $7.00 to $7.50 and gave the company a “buy” rating in a research note on Tuesday, March 5th. JPMorgan Chase & Co. decreased their price target on Akoya Biosciences from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 6th. Finally, Morgan Stanley lowered their price target on Akoya Biosciences from $8.00 to $4.00 and set an “overweight” rating for the company in a report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.25.
View Our Latest Report on Akoya Biosciences
Akoya Biosciences Company Profile
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.
Recommended Stories
- Five stocks we like better than Akoya Biosciences
- EV Stocks and How to Profit from Them
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- How to Choose Top Rated Stocks
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How Investors Can Find the Best Cheap Dividend Stocks
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.